Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GZMO -- Ignore unavailable to you. Want to Upgrade?

To: jeffbas who wrote (150)	10/21/1999 5:39:00 PM
From: Pseudo Biologist	Respond to of 438

That's right. The reported trial used a retrovirus ex-vivo. They now want to use an adenovirus vector for in-vivo gene transfer. Obviously, the latter is more convenient and cost effective. Not clear from where I sit if the second-generation approach should be superior efficacy-wise; convenience and cost-wise, no question about it. I am still puzzled that there was no company PR on this. Sure, CEGE is not cooked yet, and CEGE itself, in the past quite a touty bunch, has no motivation to do much PR these days. No problem, more time to nibble. Still working on that valuation model, BTW. PB